Jasper Files Kira Financials: Going Concern Doubt and $206.8M Pro Forma Loss
JSPR sits 90% above its 52-week low of $0.315 on light trading volume (0.2× avg).
Summary
Jasper filed the required financial statements for its Kira acquisition, revealing a going concern doubt at Kira and a pro forma combined net loss of $206.8M for FY2025.
Key Events · M&A and Partnerships · JSPR
-
Kira Financials Filed with Going Concern Doubt
Audited financial statements for Kira Pharmaceuticals show an accumulated deficit of $180.8M as of December 31, 2025, and EisnerAmper's audit report includes an explanatory paragraph about substantial doubt regarding Kira's ability to continue as a going concern.
-
Pro Forma Combined Loss of $206.8M
The unaudited pro forma condensed combined statement of operations for FY2025 shows a net loss of $206.8M, driven by a $125.2M acquired in-process R&D expense and a $1.5M transaction adjustment.
-
Pro Forma Stockholders' Deficit of $121.5M
The pro forma combined balance sheet as of June 30, 2026 shows a stockholders' deficit of $121.5M, reflecting the combined accumulated deficits of Jasper ($320.6M) and Kira ($184.2M) offset by the $132M PIPE proceeds.
-
Kira H1 2026 Net Loss of $3.4M
Kira's unaudited financial statements for the six months ended June 30, 2026 show a net loss of $3.4M and cash of $10.7M, with a $2.2M loss on issuance of SAFEs.
Analysis · JSPR · Life Sciences
This 8-K/A completes the required financial disclosures for the July 16 Kira merger. The newly filed audited financials reveal that Kira's independent auditor, EisnerAmper, included a going concern explanatory paragraph for FY2025, and the pro forma combined statements show a $206.8M net loss for FY2025 with a $121.5M stockholders' deficit. For a company already facing Nasdaq delisting risk and a pending reverse stock split vote, the addition of a going concern doubt at the acquired entity compounds the financial distress picture.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.7% of the 1024 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.9M. The 52-week trading range was $0.32 to $2.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.